The use of dasatinib treatment in breast cancer has been pre-clinically and clinically tested for both triple-negative (as monotherapy or with chemotherapy) [38, 39] and HER2+ breast cancer (as monotherapy or with trastuzumab and paclitaxel) [40, 41]. This evidence concerns the gene ERBB2 and breast cancer.